Mr. Speaker, yesterday, I came to the House floor to announce that New Jersey had just become the first state in the nation to distribute public funds for human embryonic stem cell research. I wanted to include in the Record a list of the…
Mr. Speaker, yesterday, I came to the House floor to announce that New Jersey had just become the first state in the nation to distribute public funds for human embryonic stem cell research.
I wanted to include in the Record a list of the scientists who will receive these stem cell research grants. All grants are approximately $300,000. The scientists, work at a number of different institutions around New Jersey: Rutgers University, New Jersey Institute of Technology, The Coriell Institute for Medical Research, Princeton University, UMDNJ-RWJMS, Amorcyte, Inc.
The New Jersey Commission on Science and Technology voted in a public meeting to--award Stem Cell Research Grants to the following:
T. Arinzeh, Nanofiber Scaffold for Stem Cell Based
Cartilage Repair, To test whether stem cells can be used to
repair cartilage defects with the potential for providing new
tissue engineering therapies that could help cancer patients
who have had tumors removed from bones, osteoporosis and
other cartilage and tendon damage.
R. Cohen, Training in Human Embryonic Stem Cell Biology, To
provide basic and advanced training in the field of human
embryonic stem cell biology and to develop a well-trained
pool of scientists in New Jersey proficient in hESC culture
techniques with the goal of advancing New Jersey's leadership
in stem cell research.
R.Hart, Regulation of microRNA Gene Expression in
Differentiating Neural Stem Cells, To understand and control
differentiation of neural stem cells with the potential to
produce specific cell types for therapeutic transplant in
brain trauma, stroke, spinal cord injury, Parkinson's and
Alzheimer's disease.
H. Houbaviy, MicroRNAs MiR-290-295 in Blastocyst-Derived
Stem Cells and the Early Mouse Embryo, To understand stem
cell development and lineage determination with the goal of
expanding and improving knowledge of areas of stem cell
biology currently not well understood.
I. Lemischka, Genome-Wide Functional Analysis of ES Cell
fate Regulation, To understand human embryonic stem cell
decisions such as survival/death, renewal/determination and
to understand how to maintain or induce specific cell fate
with the goal of applying this knowledge to patient
therapies.
R. McKinnon, Gliogenic Potential of Human Placental Stem
Cells, to identify mechanisms of glial cell generation from
human placental cells with the goal of identifying a
potential alternative to embryonic stem cells for clinical
trials. In collaboration with Celgene, a New Jersey-based
biotech firm ranked sixth largest internationally.
K. Moore, Interactive Mechanisms of Stem Cells and
Microenvironments, to further understand the mechanisms of
stem cell self-renewal and commitment toward the purpose of
developing new therapies or advancing existing therapies for
use in drug development and for gene and cell therapy for
immunological and other diseases.
R. Nowakowski, Molecular Circuitry of ``Stemness'' in the
Developing CNS, to learn how to reprogram or teach
transplanted cells how to generate the right type and number
of necessary cells for cell-replacement therapies with the
potential for replacing specific brain areas damaged by
disease or injury.
R. Preti, Bone Marrow Derived CD34 Cells for Treatment of
Acute Myocardial Infarction, to produce a cell therapy
product using bone marrow-derived cells for treatment of
coronary damage following a heart attack and advance the
company's federal Food and Drug Administration-approved
clinical trials with the potential for new and more effective
therapy for cardiac patients.
L. Qin, PTH-Mediated AGFR Signaling in Stromal Stem Cell
Growth and Multidifferentiation, to conduct fundamental
research using bone marrow stem cells with the potential to
develop more effective treatments for low bone mass and
similar disorders.
M. Roth, Selective Gene Delivery to Human Hematopoietic
Stem Cells, to apply novel genetic screening approaches to
stem cells with the potential of enhancing the ability to use
stem cells and gene therapy in many clinical settings,
including treating hematopoietic disorders and cancer.
J. Sadoshima, Mechanisms of Mesenchymal Stem Cell
Differentiation, to increase the efficiency of stem cell
differentiation into cardiac myocytes by manipulating a
particular signaling mechanism with the potential for
developing an effective method to repair damaged heart
tissues.
B. Saitta, Role of Extracellular Matrix in Cord Blood Stem
Cell Response to Cardiac Injury, to use stem cells derived
from umbilical cord blood to study the molecular mechanisms
of stem cells in repairing damaged areas of the heart with
the potential to heal damaged tissue and preserve or regain
function, offering an alternative to transplants which are
possible but limited by the number of donors.
M. Shen, Role of the Nodal signaling pathway in regulation
of embryonic pluripotency, to enhance fundamental
understanding of basic molecular functions in mice and human
stem cells with the potential for improving manipulation of
ES cells in culture for use in stem cell-based therapies
including possible insights into the genesis and
dysregulation of cancer stem cells.
T. Shenk, Isolation and Characterization of Life-Extended
Human Cord Blood Cells, to produce populations of stem cells
from human cord blood that can be used to study the molecular
characteristics of such cells including how to modulate these
growth responses in vivo and in culture with the potential to
improve the clinical uses of stem cells.
Y. Shi, Immunobiology of Mesenchymal Stem Cells, to
investigate the mechanisms underlying stem cell mediated
immune tolerance and its use in treatment of autoimmune
disorders with the potential to lead to new treatment for
many human diseases in which the immune system attacks the
body, including MS and asthma.
J. Tischfield, Genetic and Structural Analysis of Mouse ES
Cells and their Derivatives, to study cultured ESC and
confirm, monitor and regulate phenomena that would be
deleterious to tissues derived from stem cells with the
potential to prevent problems that could slow development of
stem cell therapies.